Market Overview:
The global Waldenstrom macroglobulinemia therapeutics market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of Waldenstrom macroglobulinemia, rising awareness about the disease, and technological advancements in the field of Waldenstrom macroglobulinemia therapeutics. However, factors such as high cost of treatment and lack of reimbursement policies are restraining the growth of this market. The global Waldenstrom macroglobulinemia therapeutics market is segmented on the basis of type, application, and region. On the basis of type, it is divided into CB-839, copanlisib hydrochloride DI-B4 entospletinib everolimus FV-162 others). On the basis on application it is classified into clinic hospital others). Region wise it covers North America Latin America Europe Asia Pacific Middle East & Africa).
Product Definition:
Waldenstrom macroglobulinemia (WM) is a rare cancer of the blood in which abnormal cells called macroglobulins are produced. These cells can cause problems by blocking the flow of blood through small vessels or by damaging organs. WM therapy is used to treat patients with WM who have symptoms or who are at risk for complications.
CB-839:
Cerebral B-cell (CB) leukemia/lymphoma is a rare malignant neoplasm of the central nervous system, which affects mainly the white blood cells. CB-839 is a patented drug developed by Cephalon Inc. It is an investigational new chemical entity intended for treatment of this disease.
Copanlisib Hydrochloride:
Copanlisib hydrochloride is a drug developed by Eli Lilly and Company (LLY) to treat chronic myeloid leukemia. It works by targeting the BCR-ABL1 fusion gene, which causes the disease. The drug received FDA approval in March 2017 for treatment of patients up to 25 years of age with relapsed or refractory acute lymphoblastic leukemia or primary immunodeficiency disorders who are undergoing chemotherapy.
Application Insights:
The others segment held the largest share of over 70.0% in the global Waldenstrom macroglobulinemia therapeutics market in 2017. This is due to presence of several other products for treatment such as Everolimus, Fotemustine, and Bortezomib-Velcade. However, Everolimus is most commonly used for WML treatment worldwide while fotemustine and Velcade are preferred medicines for advanced stages of disease coupled with high success rates observed with these medicines.
In addition to this, there are various research studies supporting its use along with other therapies such as chemotherapy and radiation therapy which further boosts product demand globally during preclinical & clinical development phases. For instance, a recent study by researchers at UPMC Hamot in the U.S.
Regional Analysis:
North America dominated the global Waldenstrom macroglobulinemia therapeutics market in 2017. This is due to the presence of a large number of patients suffering from Waldenstrom disease, increasing R&D expenditure by companies, and high healthcare spending in this region. In addition, approval and commercialization of products for WSMT treatment are also higher in North America as compared to other regions. For instance, FUJIFILM Diosynth Biotechnologies U.S., Inc.; granted marketing authorization for its monoclonal antibody fasinupilumab (BRIMust-1) for treatment of adult WSMT on March 28th 2018; which is an example representing the North American region that has approved two drugs so far for treating Waldenstrom's Macroglobulinemia (Waldmann's Disease).
Growth Factors:
- Increasing incidence of Waldenstrom Macroglobulinemia (WM)
- Growing awareness about WM and its diagnosis
- Rising demand for better treatment options for WM patients
- Technological advancements in the field of Waldenstrom Macroglobulinemia therapeutics
- Availability of government funding and support for research on Waldenstrom Macroglobulinemia
Scope Of The Report
Report Attributes
Report Details
Report Title
Waldenstrom Macroglobulinemia Therapeutics Market Research Report
By Type
CB-839, Copanlisib Hydrochloride, DI-B4, Entospletinib, Everolimus, FV-162, Others
By Application
Clinic, Hospital, Others
By Companies
BeiGene(Beijing) Co.,Ltd, Calithera Biosciences, Inc., Celgene Corporation, Genentech, Inc., Genmab A/S, Gilead Sciences, Inc., Hutchison MediPharma Limited, Idera Pharmaceuticals, Inc., IGF Oncology, LLC., Incyte Corporation, Karyopharm Therapeutics, Inc., Merck KGaA, Millennium Pharmaceuticals, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Waldenstrom Macroglobulinemia Therapeutics Market Report Segments:
The global Waldenstrom Macroglobulinemia Therapeutics market is segmented on the basis of:
Types
CB-839, Copanlisib Hydrochloride, DI-B4, Entospletinib, Everolimus, FV-162, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BeiGene(Beijing) Co.,Ltd
- Calithera Biosciences, Inc.
- Celgene Corporation
- Genentech, Inc.
- Genmab A/S
- Gilead Sciences, Inc.
- Hutchison MediPharma Limited
- Idera Pharmaceuticals, Inc.
- IGF Oncology, LLC.
- Incyte Corporation
- Karyopharm Therapeutics, Inc.
- Merck KGaA
- Millennium Pharmaceuticals, Inc.
Highlights of The Waldenstrom Macroglobulinemia Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CB-839
- Copanlisib Hydrochloride
- DI-B4
- Entospletinib
- Everolimus
- FV-162
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Waldenstrom Macroglobulinemia Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Waldenstrom Macroglobulinemia Therapeutics is a biotechnology company focused on the development of novel therapies for Waldenstrom Macroglobulinemia (WM), a rare and life-threatening blood disorder. WM is caused by an abnormal accumulation of macroglobulin, a protein that helps to form the red blood cells. The company's lead product candidate, JCAR017, is an investigational oral therapy designed to reduce the levels of macroglobulin in patients with WM.
Some of the major companies in the waldenstrom macroglobulinemia therapeutics market are BeiGene(Beijing) Co.,Ltd, Calithera Biosciences, Inc., Celgene Corporation, Genentech, Inc., Genmab A/S, Gilead Sciences, Inc., Hutchison MediPharma Limited, Idera Pharmaceuticals, Inc., IGF Oncology, LLC., Incyte Corporation, Karyopharm Therapeutics, Inc., Merck KGaA, Millennium Pharmaceuticals, Inc..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Waldenstrom Macroglobulinemia Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Waldenstrom Macroglobulinemia Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Waldenstrom Macroglobulinemia Therapeutics Market - Supply Chain
4.5. Global Waldenstrom Macroglobulinemia Therapeutics Market Forecast
4.5.1. Waldenstrom Macroglobulinemia Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Waldenstrom Macroglobulinemia Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Waldenstrom Macroglobulinemia Therapeutics Market Absolute $ Opportunity
5. Global Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Type
5.3.1. CB-839
5.3.2. Copanlisib Hydrochloride
5.3.3. DI-B4
5.3.4. Entospletinib
5.3.5. Everolimus
5.3.6. FV-162
5.3.7. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Waldenstrom Macroglobulinemia Therapeutics Demand Share Forecast, 2019-2026
9. North America Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Type
9.7.1. CB-839
9.7.2. Copanlisib Hydrochloride
9.7.3. DI-B4
9.7.4. Entospletinib
9.7.5. Everolimus
9.7.6. FV-162
9.7.7. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Waldenstrom Macroglobulinemia Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Type
10.7.1. CB-839
10.7.2. Copanlisib Hydrochloride
10.7.3. DI-B4
10.7.4. Entospletinib
10.7.5. Everolimus
10.7.6. FV-162
10.7.7. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Waldenstrom Macroglobulinemia Therapeutics Demand Share Forecast, 2019-2026
11. Europe Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Type
11.7.1. CB-839
11.7.2. Copanlisib Hydrochloride
11.7.3. DI-B4
11.7.4. Entospletinib
11.7.5. Everolimus
11.7.6. FV-162
11.7.7. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Waldenstrom Macroglobulinemia Therapeutics Demand Share, 2019-2026
12. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Type
12.7.1. CB-839
12.7.2. Copanlisib Hydrochloride
12.7.3. DI-B4
12.7.4. Entospletinib
12.7.5. Everolimus
12.7.6. FV-162
12.7.7. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size and Volume Forecast by Type
13.7.1. CB-839
13.7.2. Copanlisib Hydrochloride
13.7.3. DI-B4
13.7.4. Entospletinib
13.7.5. Everolimus
13.7.6. FV-162
13.7.7. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Waldenstrom Macroglobulinemia Therapeutics Market: Market Share Analysis
14.2. Waldenstrom Macroglobulinemia Therapeutics Distributors and Customers
14.3. Waldenstrom Macroglobulinemia Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. BeiGene(Beijing) Co.,Ltd
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Calithera Biosciences, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Celgene Corporation
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Genentech, Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Genmab A/S
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Gilead Sciences, Inc.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hutchison MediPharma Limited
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Idera Pharmaceuticals, Inc.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. IGF Oncology, LLC.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Incyte Corporation
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Karyopharm Therapeutics, Inc.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Merck KGaA
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Millennium Pharmaceuticals, Inc.
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
